APAC Pharmaceutical Drug Delivery Market

The Asia Pacific (APAC) pharmaceutical drug delivery market is projected to reach USD 687.9 million by 2031 from USD 479.7 million in 2026 at  a CAGR of  7.5% during the forecast period.

To know about the assumptions considered for the study download the pdf brochure

The APAC pharmaceutical drug delivery market region experienced moderate growth, despite facing regional challenges and imbalances. Nevertheless, it continues to be driven by rising rates of chronic illnesses, biologics and biosimilars adoption, and a rapid transition towards more advanced drug-delivery devices and technologies. Healthcare spending and government emphasis on immunization and associated health services, as well as an increase in local capabilities within drug and device manufacturing and contract and development services, have also worked as additional factors. Nevertheless, regional regulatory readiness and price-conscious regional markets have acted as moderating factors.
Some of the prominent players operating in the APAC market include (US), B. Braun (Germany), Gerresheimer AG (Germany), Cipla (India), Eli Lilly and Company (US), Novartis (Switzerland), Biogen (US), Baxter International (US), West Pharmaceutical Services (US), Sun Pharmaceutical Industries (India), GlaxoSmithKline (UK).

• In February 2024, AstraZeneca acquired Gracell Biotechnologies to expand its pipeline of advanced cell therapies, strengthening its innovation capabilities and presence in China.
• In October 2023, Boehringer Ingelheim partnered with Precision Health Research to drive precision healthcare advancements in Singapore and improve patient outcomes across APAC.
• In July 2023, Bayer collaborated with Peking University to accelerate drug discovery and translational research, focusing on oncology, cardiometabolic diseases, immunology, and cell & gene therapies in China.
• In August 2022, Sanofi and Innovent Biologics entered an agreement to hasten the development of oncology medicines and strengthen Sanofi’s commercial footprint in China.

Terumo Corporation (Japan)

Terumo Corporation, a Japan-based company founded in 1921, is one of the leading companies involved in the manufacture of medical technology, including medical drug delivery systems such as syringes, needles, infusion-related devices, catheters, and prefillable syringes used throughout the APAC region. With a strong background in both engineering and manufacturing, Terumo ensures high precision and commitment while supporting the development of combination products in the pharmaceutical industry. Terumo has a wide presence across the Asia-Pacific region, comprising Japan, China, India, Singapore, Thailand, Australia, and other major markets. Its subsidiaries in different parts of the world, such as Terumo Medical Corporation in the United States, Terumo Europe NV in Belgium, Terumo Asia Holdings in Singapore, and Terumo India Pvt. Ltd. in India, further embolden its regional supply chain and customer network.

Johnson & Johnson Services,  Inc. (US)

Johnson & Johnson, through its Pharmaceuticals business with Janssen, is one of the largest and leading participants in the APAC market for pharmaceutical drug delivery, due to its broad and diverse product pipeline of advanced therapies and its ongoing efforts to innovate and develop new and efficient drug-delivery technologies. It leads in technologies and product offerings related to long-acting injectables, controlled-release, targeted drug-delivery systems, and self-administration devices. The comprehensive R&D competencies and expertise that Johnson & Johnson possesses in material science, device technology, and formulation offer immense opportunities for developing highly stable and easy-to-use drug-delivery systems for its patients. Moreover, with large production capacity and continued R&D efforts toward innovating drug-delivery devices, Johnson & Johnson plays an integral role and acts as a catalyst for transforming advancements within the US Pharmaceuticals market.

Pfizer Inc. (US)

Pfizer Inc. represents a prominent and highly influential force within the APAC market for pharmaceutical drug delivery, backed by its broad portfolio of cutting-edge therapeutics, mRNA platform leadership, and unceasing efforts toward enhancing drug-device combinations. Pfizer's pioneering role in nucleic acid-based drug delivery technologies, ranging from its Lipid Nanoparticle (LNP) platform associated with mRNA vaccines and emerging gene therapies, has catapulted Pfizer Inc. to a leading position within next-generation drug delivery technologies. At the same time, Pfizer continues to develop various oral, injectable, inhalation, and sustained-release drug formulations specifically designed to enhance bioavailability, precision therapy, and patient compliance within targeted therapeutic domains, including immunology, oncology, cardiovascular disease therapies, and infectious disease therapies. Its strong collaboration network, extensive formulation capabilities, and substantial US production base permit efficient scaling and easy access to next-generation drug delivery technologies. Equally noteworthy are Pfizer's ongoing efforts to enhance digital health convergence, self-administration methods, and next-generation biologics drug delivery technologies, making it an unmatched and highly progressive force within Pfizer Inc. in the broader APAC market for pharmaceutical drug delivery technologies.

Market Ranking

In the APAC market for pharmaceutical drug delivery, major participants such as Terumo, BD, Nipro, B. Braun, and Baxter significantly contribute to the market's growth through their standards and innovations. Their R&D advancements have accelerated the adoption of technologies in the APAC region. Unlike smaller or lesser-ranking competitors, these market leaders possess highly developed R&D and a well-established regulatory process. Their distribution networks and reliability have enabled them to influence market dynamics. Moreover, they continually invest and focus on modernizing and innovating to achieve better market performance and a competitive advantage.

Related Reports:

Asia Pacific Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Auto Injectors), Implantable, Transmucosal, Nasal, Syringes], Application [Cancer, Diabetes], Care Setting [Hospital, Home Care]-Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com